ES2071038T3 - Peptidos asociados al hiv. - Google Patents

Peptidos asociados al hiv.

Info

Publication number
ES2071038T3
ES2071038T3 ES90311056T ES90311056T ES2071038T3 ES 2071038 T3 ES2071038 T3 ES 2071038T3 ES 90311056 T ES90311056 T ES 90311056T ES 90311056 T ES90311056 T ES 90311056T ES 2071038 T3 ES2071038 T3 ES 2071038T3
Authority
ES
Spain
Prior art keywords
leu
lys
glu
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90311056T
Other languages
English (en)
Inventor
Paul H Naylor
Su Sun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Washington University
Viral Technologies Inc
Original Assignee
George Washington University
Viral Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23666609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2071038(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by George Washington University, Viral Technologies Inc filed Critical George Washington University
Application granted granted Critical
Publication of ES2071038T3 publication Critical patent/ES2071038T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LOS FRAGMENTOS DE PROTEINA P17 DEL HIV QUE VARIAN EN LONGITUD DESDE UNOS 12 A UNOS 14 AMINOACIDOS SE UTILIZAN PARA FORMAR DIAGNOSTICOS Y VACUNAS PARA LA DETECCION Y TRATAMIENTO DEL SIDA. FRAGMENTOS PEPTIDOS ESPECIFICOS SE EXTIENDEN DESDE EL TERMINAL N HASTA EL TERMINAL C. LOS PEPTIDOS QUE TIENEN LAS SECUENCIAS DE AMINOACIDOS QUE SE MUESTRAN EN LAS FORMULAS (I), (II), (III), (IV) Y (V) SIGUIENTES: TYR-SER-VAL-HIS-GLN-ARG-LLE-ASP-VAL-LYS-ASP-THR-LYS-GLU-ALA-LEU-GLY-LYS-LLE -GLU-GLU-GLU-GLN-ASN-LYS-SER-LYS-LYS-LYS-ALA GLY-ALA-ARG-ALA-SER-VAL-LEU-SER-GLY-GLY-GLU-LEU-ASP-ARG-TRP-GLU-LYS-LLE-ARG -LEU-ARG-PRO-GLY-GLY-LYS-LYS-LYS-TYR-LYS-LEU-LYS-HIS LLE-VAL-TRP-ALA-SER-ARG-GLU-LEU-GLU-ARG-PHE-ALA-VAL-ASN-PRO-GLY-LEU-LEU GLU-THR-SER-GLU-GLY-CYS-ARG-GLN-LLE-LEU-GLY-GLN-LEU-GLN-PRO-SER-LEU-GLN-THR -GLY-SER-GLU-GLU-LEU-ARG-SER-LEU-TYR-ASN-THR-VAL-ALA-THR-LEU ALA-GLN-GLN-ALA-ALA-ALA-ASP-THR-GLY-HIS-SER-SER-GLN-VAL-SER-GLN-ASN-TYR SON INMUNOREACTIVOS A ANTICUERPOS EN LOS PACIENTES QUE SON SEROPOSITIVOS ALA P17 DEL HIV-1.
ES90311056T 1989-10-12 1990-10-09 Peptidos asociados al hiv. Expired - Lifetime ES2071038T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42046989A 1989-10-12 1989-10-12

Publications (1)

Publication Number Publication Date
ES2071038T3 true ES2071038T3 (es) 1995-06-16

Family

ID=23666609

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90311056T Expired - Lifetime ES2071038T3 (es) 1989-10-12 1990-10-09 Peptidos asociados al hiv.

Country Status (17)

Country Link
EP (3) EP0620010A1 (es)
JP (1) JPH03209398A (es)
KR (1) KR910007962A (es)
CN (1) CN1052310A (es)
AT (1) ATE119166T1 (es)
AU (1) AU6393990A (es)
CA (1) CA2027455A1 (es)
DE (1) DE69017352T2 (es)
DK (1) DK0426314T3 (es)
ES (1) ES2071038T3 (es)
GB (1) GB2236754A (es)
GR (1) GR3015244T3 (es)
HU (1) HUT55035A (es)
IE (1) IE67533B1 (es)
IL (1) IL95890A0 (es)
NZ (1) NZ235538A (es)
ZA (1) ZA907944B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4039925A1 (de) * 1990-12-14 1992-06-17 Behringwerke Ag Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
FR2734281B1 (fr) * 1995-05-18 1997-07-25 Commissariat Energie Atomique Fragments d'acide nucleique derives du genome du virus vih-1, peptides correspondants et leurs applications en tant que reactifs d'evaluation du risque de transmission materno-foetale du vih-1
US6103239A (en) * 1996-08-09 2000-08-15 Cel-Sci Corporation Modified HGP-30 heteroconjugates, compositions and methods of use
NO314588B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
EP1417222B1 (en) * 2001-08-07 2010-08-18 Medestea Internazionale S.p.A. Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62164696A (ja) * 1986-01-06 1987-07-21 エフ．ホフマン　―　ラ　ロシュ　アーゲー ＨＴＬＶ−３ｇａｇ遺伝子の発現
NZ220200A (en) * 1986-05-19 1990-08-28 Viral Technologies Inc Hiv related peptides, antibodies to the peptides and vaccines therefrom
EP0273716B1 (en) * 1986-12-30 1993-08-11 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection

Also Published As

Publication number Publication date
HU906421D0 (en) 1991-04-29
HUT55035A (en) 1991-04-29
CN1052310A (zh) 1991-06-19
DE69017352T2 (de) 1995-10-05
AU6393990A (en) 1991-04-18
EP0426314A2 (en) 1991-05-08
GR3015244T3 (en) 1995-06-30
EP0426314A3 (en) 1991-07-24
GB2236754A (en) 1991-04-17
EP0620010A1 (en) 1994-10-19
ZA907944B (en) 1991-10-30
EP0426314B1 (en) 1995-03-01
CA2027455A1 (en) 1991-04-13
DK0426314T3 (da) 1995-03-27
IE67533B1 (en) 1996-04-03
ATE119166T1 (de) 1995-03-15
DE69017352D1 (de) 1995-04-06
NZ235538A (en) 1992-06-25
IE903604A1 (en) 1991-04-24
IL95890A0 (en) 1991-07-18
KR910007962A (ko) 1991-05-30
GB9021942D0 (en) 1990-11-21
JPH03209398A (ja) 1991-09-12
EP0620009A1 (en) 1994-10-19

Similar Documents

Publication Publication Date Title
AR247590A1 (es) Una secuencia de adn que codifica derivados de factor viii humano recombinante y un procedimiento para su obtencion
ATE373010T1 (de) Gag-antigen und dessen verwendung zum nachweis von lav-infektion, sowie in immunogenen zusammensetzungen
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
NO891711L (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
GB2255093A (en) Hiv-1 core protein fragments
CY1110927T1 (el) Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων
ATE134195T1 (de) Peptidfragmente von hiv
ATE185148T1 (de) Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine
ES2071038T3 (es) Peptidos asociados al hiv.
ATE103294T1 (de) Peptidfragmente von hiv.
DE69508382D1 (de) Peptomere mit erhöhter immunogenizität
ES2095899T3 (es) Peptidos de la proteina gag de vih, su preparacion y uso.
DE69330348D1 (de) Verwendung von Peptiden welche eine Immunantwort bewirken zur Herstellung von Medikamenten zur Induzierung der Immunsuppression.
PT87239A (pt) Process for the preparation of peptides
YU64192A (sh) Analozi insulina
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 426314

Country of ref document: ES